Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 86
- Registration Number
- NCT05627635
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
- Conditions
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 312
- Registration Number
- NCT05610163
- Locations
- 🇺🇸
Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
🇺🇸Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 226
- Registration Number
- NCT05609370
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
🇨🇳Nanyang Central Hospital, Nanyang, Henan, China
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT05567835
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸Baylor St. Luke's Medical Center, Houston, Texas, United States
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
- Conditions
- Advanced Biliary Tract CarcinomaAdvanced Gallbladder CarcinomaAdvanced Intrahepatic CholangiocarcinomaRecurrent Biliary Tract CarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Hilar Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05564403
- Locations
- 🇺🇸
Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Conditions
- Metastatic HER2-Negative Breast CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Ovarian CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyDrug: AlpelisibDrug: BinimetinibProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: IpatasertibProcedure: Computed TomographyProcedure: EchocardiographyDrug: Nilotinib Hydrochloride MonohydrateBiological: PanitumumabProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: SotorasibDrug: OlaparibDrug: FluorouracilProcedure: Mutation Carrier ScreeningDrug: Neratinib MaleateDrug: LeucovorinDrug: FulvestrantProcedure: Positron Emission TomographyDrug: PalbociclibProcedure: Multigated Acquisition ScanDrug: Selumetinib SulfateDrug: Oxaliplatin
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2900
- Registration Number
- NCT05564377
- Locations
- 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT05505539
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 121
- Registration Number
- NCT05491512
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.